RARE

In the past six months, Ultragenyx's stock was impacted by several events: on September 17, 2026, the FDA granted full approval for FAYUVI™ for Sanfilippo syndrome type A, leading to a notable stock price increase. However, on September 2, 2026, the company announced that its Phase 3 Aspire results for the Angelman Syndrome drug (apazunersen) failed to meet its goals, resulting in a significant stock crash of approximately 44% and plans for substantial expense reductions. In August 2026, the company received accelerated FDA approval for GENGLYCOS™ (DTX401) for glycogen storage disease type Ia. On August 4, 2026, Ultragenyx reported its Q2 2026 financial results, with total revenue of $214 million, an increase of 28.5% year-over-year, surpassing consensus estimates. Overall, the share price declined by 52.82% between September 12, 2025, and September 11, 2026, with a 1-year change of -49.5% and a 6-month change of -26.68% as of August 5, 2026.